(MedPage Today) -- Recent approvals of trastuzumab deruxtecan (T-DXd; Enhertu) in early HER2-positive breast cancer have created new questions about its optimal use in the neoadjuvant and adjuvant settings. MedPage Today brought together three...
(MedPage Today) -- Recent approvals of trastuzumab deruxtecan (T-DXd; Enhertu) in early HER2-positive breast cancer have created new questions about its optimal use in the neoadjuvant and adjuvant settings. MedPage Today brought together three...